On the 23rd, Jingtai Technology, an AI+robot new drug and new material research and development platform, announced that it had signed a letter of intent for cooperation with DoveTree LLC, established by Gregory Verdine, a tenured professor at Harvard University, and will sign a final agreement in the near future. According to the letter of intent, Jingtai Technology will use its end-to-end artificial intelligence drug discovery platform based on AI+robots to discover and develop small molecule and antibody drug candidates for multiple targets selected by DoveTree in the fields of tumors, autoimmune diseases and neurological diseases. Jingtai Technology will receive potential development milestones and sales milestone payments of billions of dollars.